ADCs in EGFR NSCLC

Catalog

VIKTOR

ADCs in EGFR NSCLC

Podcast | English | 2025 | 36 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugates (ADCs) for EGFR-mutant non-small cell lung cancer (NSCLC). They discuss new approvals of datopotamab deruxtecan (in the United States) and sacituzumab tirumotecan (in China), key findings from the TROPION and OptiTROP trials, and emerging agents. The conversation highlights the advances in efficacy, safety, and combination strategies that are shaping the evolving treatment landscape for patients with EGFR-mutant NSCLC.

Podcast Hosts:

Stephen Liu, MD, Chief, Hematology & Oncology, Head, Developmental Therapeutics, MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Elaine Shum, MD, Assistant Professor of Medicine, Director of Cancer Screening Programs, New York University Perlmutter Cancer Center, New York, NY, USA
Li Zhang, MD, Professor, Medical Oncology Department, Sun Yat-Sen University Cancer Center, Guangzhou, China